Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Adolescent
Adult
Age of Onset
Aged
Antibodies, Antiphospholipid
/ immunology
Antirheumatic Agents
/ therapeutic use
Child
Child, Preschool
Female
Glucocorticoids
/ therapeutic use
Humans
Hydroxychloroquine
/ therapeutic use
Hypertension
/ epidemiology
Kidney Transplantation
/ statistics & numerical data
Logistic Models
Lupus Erythematosus, Systemic
/ drug therapy
Lupus Nephritis
/ epidemiology
Lupus Vasculitis, Central Nervous System
/ epidemiology
Male
Middle Aged
Multivariate Analysis
Musculoskeletal Diseases
/ epidemiology
Myocardial Infarction
/ epidemiology
Netherlands
/ epidemiology
Odds Ratio
Prednisone
/ therapeutic use
Quality of Life
Severity of Illness Index
Stroke
/ epidemiology
Young Adult
Journal
Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
04
08
2017
accepted:
21
08
2018
pubmed:
29
8
2018
medline:
5
11
2019
entrez:
29
8
2018
Statut:
ppublish
Résumé
Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long-term outcome data are limited. This study was undertaken to identify clinical characteristics and health-related quality of life (HRQoL) of adults with childhood-onset SLE. Patients participated in a single study visit comprising a structured history and physical examination. Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI-2K]), damage (scored using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL (scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed. In total, 111 childhood-onset SLE patients were included; the median disease duration was 20 years, 91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI-2K score 4), and 71% of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease-modifying antirheumatic drugs. The vast majority of new childhood-onset SLE-related manifestations developed within 2 years of diagnosis. Damage such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predominantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI-2K score ≥8) and changes in physical appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively). The majority of adults with childhood-onset SLE in this large cohort developed significant damage at a young age and had impaired HRQoL without achieving drug-free remission, illustrating the substantial impact of childhood-onset SLE on future life.
Identifiants
pubmed: 30152151
doi: 10.1002/art.40697
pmc: PMC6590133
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Antirheumatic Agents
0
Glucocorticoids
0
Hydroxychloroquine
4QWG6N8QKH
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
290-301Subventions
Organisme : Dutch Arthritis Foundation
ID : BP12-1-261
Pays : International
Organisme : National Association for LUPUS, APS, Scleroderma and MCTD (NVLE)
Pays : International
Organisme : Dutch Kidney Foundation
ID : KJPB12.028
Pays : International
Organisme : Dutch Kidney Foundation
ID : 17OKG04
Pays : International
Organisme : Netherlands Organization for Scientific Research
ID : 90713460
Pays : International
Informations de copyright
© 2018 The Authors. Arthritis & Rheumatology published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.
Références
Arthritis Rheum. 2006 Jun 15;55(3):427-33
pubmed: 16739209
Ann Rheum Dis. 2009 Dec;68(12):1800-4
pubmed: 19910301
Arthritis Rheum. 2008 Feb;58(2):556-62
pubmed: 18240232
J Rheumatol. 2005 Sep;32(9):1706-8
pubmed: 16142864
Arthritis Rheum. 2002 Feb;46(2):436-44
pubmed: 11840446
Lupus. 2010 Oct;19(11):1315-25
pubmed: 20861207
J Rheumatol. 2009 Nov;36(11):2539-46
pubmed: 19833755
Lupus. 2011 Oct;20(11):1187-92
pubmed: 21768176
J Rheumatol. 2016 Aug;43(8):1490-7
pubmed: 27252431
Ann Rheum Dis. 2017 Jan;76(1):17-28
pubmed: 27697765
J Rheumatol. 2010 Feb;37(2):296-304
pubmed: 20032098
Arthritis Care Res (Hoboken). 2018 May;70(5):750-757
pubmed: 28704581
Arthritis Rheum. 2003 Aug 15;49(4):501-7
pubmed: 12910556
Lupus. 2015 Aug;24(9):998-1005
pubmed: 25926055
Arthritis Care Res (Hoboken). 2012 Dec;64(12):1787-93
pubmed: 22730317
Pediatr Clin North Am. 2012 Apr;59(2):345-64
pubmed: 22560574
Arthritis Rheum. 2010 Feb;62(2):599-608
pubmed: 20112378
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
J Clin Epidemiol. 1998 Nov;51(11):1055-68
pubmed: 9817123
J Clin Psychol. 1984 Nov;40(6):1365-7
pubmed: 6511949
Arthritis Rheum. 2009 Jan 15;61(1):13-20
pubmed: 19116979
Arthritis Rheum. 2007 Feb 15;57(1):56-63
pubmed: 17266065
Nat Rev Rheumatol. 2010 Sep;6(9):538-46
pubmed: 20683438
Psychol Aging. 1990 Mar;5(1):58-67
pubmed: 2317302
Rheumatology (Oxford). 2009 Jun;48(6):673-5
pubmed: 19359343
Arthritis Rheum. 2012 Aug;64(8):2677-86
pubmed: 22553077
J Rheumatol. 2016 Jan;43(1):54-65
pubmed: 26568591
J Consult Clin Psychol. 2001 Dec;69(6):1026-36
pubmed: 11777106
Arthritis Care Res (Hoboken). 2013 Jul;65(7):1121-7
pubmed: 23818263
BMC Immunol. 2017 Mar 28;18(1):17
pubmed: 28351341
Semin Arthritis Rheum. 2013 Dec;43(3):352-61
pubmed: 23786872
Lupus. 2005;14(11):903-6
pubmed: 16335583
Lancet. 2007 Feb 17;369(9561):587-96
pubmed: 17307106
Arthritis Rheum. 2012 Aug;64(8):2669-76
pubmed: 22847366
Reumatol Clin. 2011 Jan-Feb;7(1):3-6
pubmed: 21794772
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Arthritis Rheum. 2000 Aug;43(8):1801-8
pubmed: 10943870
Arthritis Care Res (Hoboken). 2017 Jan;69(1):115-123
pubmed: 27390293
Arthritis Care Res (Hoboken). 2013 Jan;65(1):152-60
pubmed: 22744999
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
J Rheumatol. 2004 Aug;31(8):1650-4
pubmed: 15290748
J Rheumatol. 2016 Jun;43(6):1050-6
pubmed: 27084911
Arthritis Rheum. 2004 Jun 15;51(3):458-64
pubmed: 15188334
Arthritis Rheum. 2004 Jun 15;51(3):465-74
pubmed: 15188335
Rheumatology (Oxford). 2009 Jul;48(7):779-84
pubmed: 19416945
Arthritis Rheum. 1982 Nov;25(11):1271-7
pubmed: 7138600
J Rheumatol. 2002 Feb;29(2):288-91
pubmed: 11838846
Ann Rheum Dis. 2015 Sep;74(9):1706-13
pubmed: 24834926
Ann Rheum Dis. 2011 Oct;70(10):1704-12
pubmed: 21813547
J Health Psychol. 2005 Sep;10(5):623-31
pubmed: 16033784
Clin Exp Rheumatol. 2008 Jan-Feb;26(1):32-8
pubmed: 18328144
Lupus. 2017 Oct;26(11):1197-1204
pubmed: 28420047
Lupus. 2014;23(1):93-101
pubmed: 24197553
Rheumatol Int. 2016 Jul;36(7):955-60
pubmed: 26979603
Eur J Prev Cardiol. 2015 Nov;22(11):1435-41
pubmed: 25139772
Lupus. 2017 Mar;26(3):255-265
pubmed: 27496901
Arthritis Care Res (Hoboken). 2010 Aug;62(8):1152-9
pubmed: 20235215
J Rheumatol. 2009 Jul;36(7):1536-45
pubmed: 19487266
Rheumatol Int. 2015 Jul;35(7):1225-32
pubmed: 25586653
Arthritis Rheum. 2012 Jul;64(7):2356-65
pubmed: 22294381
Lupus. 2015 Feb;24(2):191-7
pubmed: 25335488
J Pediatr. 2008 Apr;152(4):550-6
pubmed: 18346514